{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:35:42Z","timestamp":1758476142687},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1002\/jps.24170","type":"journal-article","created":{"date-parts":[[2014,9,12]],"date-time":"2014-09-12T22:05:19Z","timestamp":1410559519000},"page":"396-406","source":"Crossref","is-referenced-by-count":7,"title":["Development of ADA Against Recombinant Human Interferon Beta in Immune Tolerant Mice Requires Rapid Recruitment of CD4+ T Cells, Induces Formation of Germinal Centers but Lacks Susceptibility for (Most) Adjuvants"],"prefix":"10.1016","volume":"104","author":[{"given":"Grzegorz","family":"Kijanka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody","family":"Sauerborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Boon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huub","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Brinks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24170_bb0005","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn\u2019s disease","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/jps.24170_bb0010","doi-asserted-by":"crossref","first-page":"vi3","DOI":"10.1093\/ndt\/gfh1092","article-title":"Factors influencing the immunogenicity of therapeutic proteins","volume":"20","author":"Schellekens","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1002\/jps.24170_bb0015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.drudis.2007.06.005","article-title":"Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses","volume":"12","author":"Barbosa","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1002\/jps.24170_bb0020","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","article-title":"Immunogenicity of therapeutic proteins: Clinical implications and future prospects","volume":"24","author":"Schellekens","year":"2002","journal-title":"Clin Ther"},{"key":"10.1002\/jps.24170_bb0025","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1097\/01.ASN.0000140219.28618.9F","article-title":"Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk","volume":"15","author":"Cournoyer","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1002\/jps.24170_bb0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00062752-200101000-00010","article-title":"Germinal center reaction","volume":"8","author":"McHeyzer-Williams","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1002\/jps.24170_bb0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev.iy.11.040193.001555","article-title":"T cell-dependent B cell activation","volume":"11","author":"Parker","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"10.1002\/jps.24170_bb0040","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4T cells: Fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"10.1002\/jps.24170_bb0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00062752-200101000-00009","article-title":"Th1 and Th2 cells","volume":"8","author":"Dong","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1002\/jps.24170_bb0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1146\/annurev.iy.13.040195.003255","article-title":"T Cell independent antigens type 2","volume":"13","author":"Mond","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.1002\/jps.24170_bb0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0952-7915(95)80109-X","article-title":"T cell independent antigens","volume":"7","author":"Mond","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1002\/jps.24170_bb0060","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/archneur.58.8.1299","article-title":"Measurement of antibodies to interferon beta in patients with multiple sclerosis","volume":"58","author":"Pachner","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1002\/jps.24170_bb0065","doi-asserted-by":"crossref","first-page":"II15","DOI":"10.1007\/s00415-004-1204-7","article-title":"Immunogenicity of interferon beta: Differences among products","volume":"251","author":"Bertolotto","year":"2004","journal-title":"J Neurology"},{"key":"10.1002\/jps.24170_bb0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jir.2010.0038","article-title":"Frequency and magnitude of interferon \u03b2 neutralizing antibodies in the evaluation of interferon \u03b2 immunogenicity in patients with multiple sclerosis","volume":"31","author":"Grossberg","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"10.1002\/jps.24170_bb0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/1352458506070762","article-title":"Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity","volume":"13","author":"Sominanda","year":"2007","journal-title":"Mult Scler"},{"key":"10.1002\/jps.24170_bb0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jim.2009.10.005","article-title":"Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta","volume":"352","author":"Van Beers","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1002\/jps.24170_bb0085","first-page":"56","article-title":"Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vi","volume":"12","author":"Perini","year":"2001","journal-title":"Eur Cytokine Netw"},{"key":"10.1002\/jps.24170_bb0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/107999001750133195","article-title":"Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b","volume":"21","author":"Deisenhammer","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"10.1002\/jps.24170_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10875-012-9783-z","article-title":"Antibody response against Betaferon\u00ae in immune tolerant mice: Involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory","volume":"33","author":"Sauerborn","year":"2013","journal-title":"J Clin Im- muno"},{"key":"10.1002\/jps.24170_bb0100","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s11095-010-0172-0","article-title":"Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice","volume":"27","author":"Van Beers","year":"2010","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24170_bb0105","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s11095-011-0523-5","article-title":"Immunogenicity of therapeutic proteins: The use of animal models","volume":"28","author":"Brinks","year":"2011","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24170_bb0110","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s11095-005-4578-z","article-title":"Development of a transgenic mouse model immune tolerant for human interferon Beta","volume":"22","author":"Hermeling","year":"2005","journal-title":"Pharml Res"},{"key":"10.1002\/jps.24170_bb0115","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.23415","article-title":"Characterization and quantitation of aggregates and particles in interferon-$ products: Potential links between product quality attributes and immunogenicity","volume":"102","author":"Barnard","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24170_bb0120","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.molimm.2008.09.023","article-title":"Reduced notch activity is associated with an impaired marginal zone B cell development and function in Sly1 mutant mice","volume":"46","author":"Scheikl","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1002\/jps.24170_bb0125","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s11095-005-8177-9","article-title":"Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b","volume":"22","author":"Hermeling","year":"2005","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24170_bb0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1086\/367701","article-title":"Immune response to capsular and surface proteins polysaccharide in patients of streptococcus pneumoniae with invasive pneumococcal disease","volume":"187","author":"Zysk","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1002\/jps.24170_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2009.11.001","article-title":"Immunological mechanism underlying the immune response to recombinant human protein therapeutics","volume":"31","author":"Sauerborn","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1002\/jps.24170_bb0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.imlet.2005.08.002","article-title":"(How) do aluminium adjuvants work?","volume":"102","author":"Brewer","year":"2006","journal-title":"Immunol Lett"},{"key":"10.1002\/jps.24170_bb0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2567.2009.03164.x","article-title":"T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection","volume":"129","author":"Korsholm","year":"2010","journal-title":"Immunology"},{"key":"10.1002\/jps.24170_bb0150","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1084\/jem.191.3.485","article-title":"Germinal Centers without T Cells","volume":"191","author":"de Vinuesa","year":"2000","journal-title":"J Exp Med"},{"key":"10.1002\/jps.24170_bb0155","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/intimm\/10.7.851","article-title":"Germinal center formation following immunization with the polysaccharide dextran B512 is substantially increased by cholera toxin","volume":"10","author":"Sverremark","year":"1998","journal-title":"Int Immunol"},{"key":"10.1002\/jps.24170_bb0160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.biotechadv.2007.01.006","article-title":"Immunogenicity of therapeutic proteins. Part 2: Impact of container closures","volume":"25","author":"Sharma","year":"2007","journal-title":"Biotechnol Adv"},{"key":"10.1002\/jps.24170_bb0165","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.intimp.2005.10.001","article-title":"An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin","volume":"6","author":"Ryan","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1002\/jps.24170_bb0170","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/BF00399790","article-title":"The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model","volume":"37","author":"Ottesen","year":"1994","journal-title":"Diabetologia"},{"key":"10.1002\/jps.24170_bb0175","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/jps.20599","article-title":"Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation","volume":"95","author":"Hermeling","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24170_bb0180","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biologicals.2010.06.002","article-title":"Mode of action of adjuvants: Implications for vaccine safety and design","volume":"38","author":"Mastelic","year":"2010","journal-title":"Biologicals"},{"key":"10.1002\/jps.24170_bb0185","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1086\/313883","article-title":"Improving vaccine performance with adjuvants","volume":"30","author":"Vogel","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.24170_bb0190","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/COH.0b013e32833d2cdb","article-title":"Role of adjuvants in modeling the immune response","volume":"5","author":"Carter","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1002\/jps.24170_bb0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4236\/wjv.2011.12007","article-title":"Selection of adjuvants for enhanced vaccine potency","volume":"01","author":"Wang","year":"2011","journal-title":"World J Vaccine"},{"key":"10.1002\/jps.24170_bb0200","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/14712598.7.10.1551","article-title":"Adjuvants in vaccines and for immunisation: Current trends","volume":"7","author":"Chiarella","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1002\/jps.24170_bb0205","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1128\/IAI.69.9.5716-5725.2001","article-title":"Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells","volume":"69","author":"George-Chandy","year":"2001","journal-title":"Infect Immun"},{"key":"10.1002\/jps.24170_bb0210","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1874226200902010094","article-title":"Gan-glioside GM1 binding peptides: A potential adjuvant for transcutaneous immunization","volume":"2","author":"Peachman","year":"2009","journal-title":"Open Immunol J"},{"key":"10.1002\/jps.24170_bb0215","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1002\/jps.21834","article-title":"Immunogenicity of Aggregates of Recombinant Human Growth Hormone in Mouse Models","volume":"98","author":"Fradkin","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24170_bb0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/IAI.69.1.297-306.2001","article-title":"Group B streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization","volume":"69","author":"Shen","year":"2001","journal-title":"Infect Immun"},{"key":"10.1002\/jps.24170_bb0225","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1128\/IAI.67.12.6375-6384.1999","article-title":"Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines","volume":"67","author":"Guttormsen","year":"1999","journal-title":"Infect Immun"},{"key":"10.1002\/jps.24170_bb0230","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1128\/IAI.66.5.2026-2032.1998","article-title":"Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model","volume":"66","author":"Guttormsen","year":"1998","journal-title":"Infect Immun"},{"key":"10.1002\/jps.24170_bb0235","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","article-title":"Regulatory T cells: How do they suppress immune responses?","volume":"21","author":"Sakaguchi","year":"2009","journal-title":"Int Immunol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915302021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915302021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T10:10:44Z","timestamp":1598263844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915302021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0022354915302021"],"URL":"https:\/\/doi.org\/10.1002\/jps.24170","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}